Welcome to our dedicated page for Regenerative Medical Technology Group SEC filings (Ticker: RMTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regenerative Medical Technologies Group, Inc. (RMTG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. RMTG is an SEC-reporting regenerative medicine company with file number 000-56010, and its filings offer detail on operations conducted through its Global Stem Cells Group subsidiary, including product sales, equipment sales, patient procedures, and physician training activities.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand how RMTG’s four main revenue channels and turnkey membership model contribute to overall performance. These reports typically describe the company’s integrated business model, which links clinical operations, product and equipment distribution, manufacturing through its CELLGENIC brand, and education and certification programs delivered via the International Society for Stem Cell Application (ISSCA).
The filings page may also include current reports on Form 8-K that disclose material events, such as new affiliate agreements, manufacturing milestones, or significant business developments, as well as proxy statements that discuss corporate governance and matters submitted to shareholders. For monitoring reporting timeliness, documents such as the company’s Form NT 10-Q notification of late filing provide context on delays in periodic reports and the expected timing of submissions.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information related to revenue sources, operating structure, and risk factors. Real-time updates from EDGAR allow users to see new filings as they are posted, while access to ownership and insider-related forms, when available, can help track management’s alignment with shareholders.
By using the RMTG SEC filings page, investors can examine the company’s official financial statements, disclosures about its regenerative medicine operations, and narrative explanations that support a more informed view of its business.
Regenerative Medical Technology Group Inc. (RMTG) reported on an investor video Q&A where management discussed growth, capital structure, and strategic initiatives rather than announcing a specific transaction. Management highlighted that Q1 2026 revenue was up 90% year over year and that Q2 2026 revenue roughly quadrupled year over year, attributing this to its education-focused ISSCA training business, product supply via Cellgenic, and clinical operations at Cellular Hope Institute.
Management acknowledged that the company carries significant liabilities, interest expense, derivatives, and fair value mark-to-market items associated with financing growth and the acquisition of Global Stem Cell Group, and said there is a plan to address this by scaling higher-margin, recurring revenue segments. The company reiterated its long-term desire to uplist to Nasdaq, noting Nasdaq’s financial and market-based checklist, but emphasized that timing and outcome cannot be guaranteed. They also described strategic investments in Cancun and Argentina, including a new laboratory relationship in Argentina under what they described as the first local license of its kind, expansion of the Cancun lab with two additional clean rooms, and ongoing global ISSCA events and the ISSCA Ai initiative built on a large anonymized medical data set. Management stated it is exploring capital-raising options and may modestly increase authorized shares from the current 100 million, after having reduced authorized shares from 6.5 billion in 2024.
Regenerative Medical Technology Group Inc. (RMTG) reported sharp top-line growth but remains highly leveraged and unprofitable for the quarter ended June 30, 2026. Quarterly revenue rose to $4.0 million from $1.0 million, and six‑month revenue increased to $6.66 million from $2.35 million, driven entirely by Global Stem Cells Group. Gross profit for the first half reached $4.34 million, a 65.2% gross margin, and operating results swung to an income from operations of $795,760 versus a loss a year earlier.
Despite this, heavy financing costs produced a larger net loss. Six‑month net loss widened to $3.22 million from $2.20 million, as interest expense more than doubled to $4.14 million. The balance sheet is highly stressed: total assets were $5.85 million against total liabilities of $45.1 million, resulting in a stockholders’ deficit of $39.3 million and a working capital deficit of $40.3 million. Accrued interest reached $19.6 million, promissory and convertible notes totaled about $19.8 million in principal, and warrant- and conversion-related derivative liabilities were $3.24 million.
Management discloses an accumulated deficit of $79.5 million and states there is substantial doubt about the company’s ability to continue as a going concern without additional debt or equity financing. Cash increased to $1.32 million, supported by new borrowing, but multiple notes are in default and further convertible debt was issued after quarter‑end, adding to potential dilution and financial risk.
Regenerative Medical Technology Group Inc. obtained written consent on August 17, 2026 from its Board and holders of 1,050,000 Series AA Preferred shares, representing 67% of voting power, to amend its Articles of Incorporation to increase authorized common stock from 100,000,000 to 400,000,000 shares and to effect a name change. There were 13,138,968 common shares outstanding as of the record date, while approximately 184,156,824 additional shares may be issuable upon conversion or exercise of outstanding notes, preferred stock and warrants, which currently exceeds the authorized amount.
The company states it is reliant on investment capital to continue as a going concern and views the larger authorization as necessary to honor existing convertible and warrant obligations and to permit future equity or convertible financings and incentive awards. The change may dilute existing stockholders and could have anti-takeover effects, as the Board will be able to issue additional shares without further stockholder approval, subject to law. No dissenters’ rights are provided. The capital increase and name change become effective no earlier than 20 days after mailing of the definitive information statement.
Regenerative Medical Technology Group Inc. submitted a notice that its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 will be filed late. The company states it was unable, without unreasonable effort or expense, to timely compile all required financial statement information and related disclosures.
The company indicates that it expects to file the Form 10-Q within the five-day grace period provided by Rule 12b-25. The notification is signed by David Christensen, who serves as President, Chief Executive Officer, Chief Financial Officer, Secretary and Director.
Regenerative Medical Technology Group Inc. reported strong top-line growth but continued losses for the three months ended March 31, 2026. Revenue rose to $2.64M, up about 93% from the prior-year quarter, driven by higher training, product supplies, and patient procedure activity at Global Stem Cells Group.
Gross profit increased to $1.77M with a gross margin near 67%, and income from operations improved to $0.23M. However, heavy financing costs dominated results: interest expense was $2.19M, partly offset by a $1.08M non-cash gain from lower derivative liability, leading to a net loss of $0.88M or $0.07 per share.
Cash was $1.06M at quarter-end, while total liabilities reached $40.63M, including approximately $21.46M of promissory notes and $18.02M of accrued interest. The company reports a working capital deficit of about $36.64M and an accumulated deficit of $76.24M, and it states that these factors raise substantial doubt about its ability to continue as a going concern without additional financing.
Regenerative Medical Technology Group Inc. submitted a Form NT 10-Q notifying the SEC of a late Quarterly Report for the period ended March 31, 2026. The company states it could not, without unreasonable effort or expense, timely compile required financial statements and expects to file within the five-day grace period allowed by Rule 12b-25. The notification is signed by David Christensen on May 15, 2026.
Regenerative Medical Technology Group Inc. reports 2025 revenue of $5,100,315, up 24.17%, driven by international training, product sales, and patient procedures, but gross profit was flat and operating expenses rose 34.14%, leading to a loss from operations of $867,162.
Heavy leverage and financing costs dominated results, with interest expense of $7,447,780 and a net loss of $7,812,409. The auditor raised substantial doubt about the company’s ability to continue as a going concern, and $1,157,935 of unsecured notes are in default, with potential acceleration of up to $16.6M in secured debt. All revenue is generated outside the U.S., adding foreign exchange, regulatory, and geopolitical risk. Shareholders face significant dilution risk from large outstanding options, warrants, and convertibles, while the stock trades as an illiquid penny stock on the OTC Pink market.
Regenerative Medical Technology Group Inc. notified the SEC of a late filing for its Form 10-K for the period ended December 31, 2025. The company states it could not, "without unreasonable effort or expense," timely compile required financial statements and related disclosures and expects to file within the fifteen-day grace period under Rule 12b-25.
The notification was signed by David Christensen on March 31, 2026. Contact details provided include a Boca Raton address and phone number.
Regenerative Medical Technology Group Inc. (RMTG) reports higher revenue but deepening losses for the nine months ended September 30, 2025. Revenue rose to $3,528,393 from $2,596,671, driven entirely by Global Stem Cells Group, with growth in training, product supplies, and patient procedures. Cost of revenue increased, but the company still generated gross profit of $2,031,283.
Operating expenses climbed to $2,592,171, and heavy interest and financing costs pushed total other expense to $5,858,678, resulting in a net loss of $6,419,566 versus $4,924,785 a year earlier. The balance sheet shows assets of $4,519,827 against total liabilities of $34,574,268 and a stockholders’ deficit of $30,054,441. The company discloses a working capital deficit of $15,762,714 and an accumulated deficit of $73,972,668 and states there is substantial doubt about its ability to continue as a going concern.
Regenerative Medical Technology Group Inc. (RMTG) filed a Form 12b-25 (NT 10-Q) for its Quarterly Report for the period ended September 30, 2025.
The company says it could not, without unreasonable effort or expense, complete the financial statements and related disclosures. It expects to file the Form 10-Q within the five-day grace period provided by Rule 12b-25.